UltraSight raises $24M Series B2 to scale AI-guided cardiac ultrasound

UltraSight announced a $24 million Series B2 financing led by Alive HealthTech Growth Fund to expand commercial adoption of its FDA-cleared AI-guided cardiac ultrasound Echosystem across U.S. health systems.

HEALTH desk — hospitals still wait on scarce sonographers for basic heart imaging; UltraSight is betting AI guidance lets more clinicians capture usable echoes at the bedside, and investors just put another $24M behind that workflow.

Who wrote the checks, in the release’s order. Alive HealthTech Growth Fund led. New participants named on the wire: Deep Insight, Star51 Capital, Connecticut Innovations, and eHealth Ventures. Existing investors who also participated: Mayo Clinic Ventures, NYU, and Iron Nation. A lead is the investor the company names first. A participant wrote a check. An existing investor was already on the cap table, which is the list of who owns what. The page does not say how the $24 million splits, and it does not say whether NYU means the university, a venture fund, or both. Do not invent the split or a middle name for NYU.

What the money is for, in the release’s words. The financing supports commercial expansion in the United States, and it funds new high-value workflows for the intensive care unit and for circulatory support. An intensive care unit, shortened to ICU, is the hospital ward for the sickest patients. Circulatory support is the machines and the care that help a failing heart move blood. The release says time-critical imaging decisions in those rooms shape how a patient is managed. The proceeds also support strategic collaborations so the Echosystem product line can spread as the company adds its own AI across time-critical cardiac care pathways. A pathway, here, is the sequence of steps a heart patient moves through. These are plans on a press release. They are not a hospital contract this desk read.

What the Echosystem is. UltraSight calls itself an AI-powered cardiac workflow company. Cardiac means the heart. The product is the UltraSight Echosystem. The about box says it combines structured training, real-time AI guidance, and advanced analytics so any clinical provider can perform a focused echocardiography exam under qualified physician oversight. Echocardiography, which clinics shorten to echo, is an ultrasound of the heart: sound waves, not radiation, that make a moving picture of the chambers and the valves. Focused means a shorter exam aimed at a specific question, not the full study a specialist runs in the echo lab. A clinical provider, here, is a clinician who is not necessarily that specialist. Qualified physician oversight means a doctor still owns the read. The about box says the software supports diagnostic-quality images at the bedside while a physician still interprets and reports in real time. Diagnostic-quality is the company’s bar for an image a doctor can use. The settings it names are inpatient, outpatient, oncology, critical care, and screening. Inpatient is a stay in the hospital. Outpatient is a visit that does not include a stay. Oncology is cancer care. Screening is looking before a person is obviously sick. These lines are the company’s. This desk did not scan a patient.

The clearance, and where the company says the software already sits. The about box says UltraSight’s software has FDA 510(k) clearance to assist medical professionals in performing cardiac ultrasound scans. A 510(k) is the FDA path that lets a device be sold because the agency finds it similar enough to one already on the market. It is a clearance. It is not a drug approval, and it is not a promise that every scan will be right. The subhead says the financing builds on “FDA clearances,” plural, plus clinical evidence and commercial traction. The about box prints one clearance sentence and does not name a second device or a second submission number. Do not invent a second clearance. The release says the Echosystem is deployed across more than 10 commercial sites spanning intensive care settings. More than 10 is the company’s count. Spanning intensive care means those sites include ICU work. The page does not print the hospital names. Do not invent them.

The study the release cites, and whose numbers they are. UltraSight says it keeps producing evidence that trained clinicians who are not sonographers can acquire diagnostic-quality heart images with AI guidance. A sonographer is the specialist whose job is to capture those images. The release points at a paper in JAMA Cardiology, dated Aug. 28, 2026: Lee, Naser, Kane, and coauthors, “Artificial Intelligence–Enabled Acquisition and Interpretation for Screening Aortic Stenosis,” DOI 10.1001/jamacardio.2026.3829. The release says novice operators using AI-guided cardiac ultrasound acquired high-quality images for automated detection of moderate or greater aortic stenosis, with 93 percent sensitivity and 96 percent specificity. A novice, here, is someone without the usual imaging training. Aortic stenosis is a narrowed aortic valve, so the heart has to push harder to send blood out to the body. Moderate or greater means the narrowing is not a mild one. Sensitivity of 93 percent means the test caught about 93 of every 100 people who had that narrowing, if the rate in the paper holds. Specificity of 96 percent means it correctly cleared about 96 of every 100 people who did not. The release does not print how many people were in the study. Do not turn “of every 100” into a headcount. This desk did not re-read the journal. The journal page this desk opened stopped at a bot check. The 93 and the 96 stay the wire’s citation of that paper. They are not a recount this desk ran, and they are not a result for every heart condition.

Who is quoted, and who joins the board. Davidi Vortman is chief executive and co-founder. He said the company is entering this next stage as its FDA-cleared portfolio keeps expanding to broader cardiac imaging workflows, and that the financing is meant to turn that momentum into wider adoption, deeper collaborations, and greater access to high-quality cardiac ultrasound for patients who cannot afford to wait. That is his aim. It is not a wait-time this desk measured. Dudi Klein, Alive co-founder and managing partner, said UltraSight combines clinical evidence with a scalable commercial model in a market limited by access and by too few trained people, and that the technology, the leadership, and the collaborations position the company to support cardiac workflows across care settings. “We believe” is his. Professor Rafi Beyar, an interventional cardiologist and a general partner at Alive, said UltraSight has the potential to change how imaging supports diagnosis and treatment in structural heart disease, where a good heart ultrasound in the moment still matters. Structural heart disease is disease of the valves and the walls, not only the arteries. Potential is his word. Rick Geoffrion was recently appointed chairman. The release says he brings more than 30 years in cardiovascular devices, across interventional cardiology, circulatory support, structural heart, and commercialization. Recently is the release’s word. It does not print the day he took the chair. He said access to reliable ultrasound, for diagnosis and for treatment, still depends on a scarce group of experts, and that this has constrained the scale-up of cardiac care for 20 years. Scarce, and 20 years, are his framing. The board will also welcome Klein; Tal Wenderow, founding managing partner of Star51 Capital; and Barak Ben-Eliezer, managing partner at Deep Insight. “Will welcome” is the tense on the wire. This desk did not sit in a board meeting.

The Mayo line, printed on the release, not buried. Mayo Clinic has a financial interest in the technology this press release describes. The disclosure says Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research. A financial interest means the clinic can gain if the technology makes money. The page says so. It does not print the size of that interest, a royalty rate, or an equity percent. Do not invent them. Mayo Clinic Ventures is also named as an existing investor in the round. The disclosure and the investor line are two sentences. Do not collapse them into one dollar figure.

What the company homepage adds, and only the homepage. ultrasight.com spells the product EchoSystem, with a capital S in System. The wire spells Echosystem. File each spelling with its page. The homepage this desk read puts the company at One Broadway, 14th Floor, Cambridge, MA 02142, and prints info@ultrasight.com. Cambridge is the Boston-area address. The wire’s dateline is Boston. The San Clemente, California, address on the wire is the media contact, Putnam Insights, not a second headquarters. The homepage says that after minimal training with real-time AI guidance, novice users in a pivotal study acquired diagnostic-quality images in the majority of patients. Majority is the homepage’s word. It does not print the percent. The same page says twelve studies presented at ACC, ASE, and ESC in 2026, including a JAMA Cardiology publication, show that people with no prior imaging experience, guided by UltraSight’s AI, can acquire a diagnostic-quality heart ultrasound in under five minutes and screen for aortic stenosis, hypertrophic cardiomyopathy, low ejection fraction, and left-ventricular enlargement. Hypertrophic cardiomyopathy is a thickened heart muscle. Ejection fraction is the share of blood the left ventricle pushes out with each beat. Low means that share is down. Left-ventricular enlargement means that chamber is bigger than it should be. Under five minutes, and twelve studies, are the homepage’s. The page does not name the twelve. A later sentence says that in the first head-to-head trial of two FDA-cleared AI guidance systems, UltraSight beat the comparator on image quality, feasibility, and accuracy for detecting ejection fraction. The page does not name the other system and does not print the scores. Under that sentence the homepage says the work was published in Circulation: Cardiovascular Imaging, an American Heart Association journal. That journal line is the homepage’s. It is not the wire’s Aug. 28 JAMA Cardiology citation. Do not merge the two papers. The homepage also says trained ICU staff perform FoCUS inside the workflow they already have. FoCUS is the short name for a focused cardiac ultrasound, the same idea as the focused echocardiography exam in the wire’s about box.

Plain English for the rest of the card: Series B2 = another private growth round at the B stage, not a public listing. $24 million = the raise the release announced. It is not a valuation. echo = an ultrasound of the heart. focused = a shorter exam aimed at one question. sonographer = the specialist trained to capture those images. ICU = the ward for the sickest patients. circulatory support = help for a failing heart and circulation. 510(k) = an FDA clearance based on similarity to a device already sold, not a drug approval. aortic stenosis = a narrowed valve leaving the heart. sensitivity = the share of sick people the test catches. specificity = the share of well people the test correctly clears. 93 percent and 96 percent = the wire’s account of the Aug. 28 JAMA Cardiology paper, not a recount here. novice = a user without the usual imaging training. FoCUS = focused cardiac ultrasound. ejection fraction = how much blood the left ventricle pumps out each beat. The homepage’s under-five-minutes line, the twelve studies, the unnamed comparator, and the Circulation journal line stay on that page. This filing is the 23 Sep announcement. It is not a promise that every bedside scan replaces a full echo lab.

PRIMARY here: UltraSight’s 23 Sep 2026 EIN Presswire release, stamped 12:00 GMT and datelined Boston — Tier A PRIMARY, the company’s own record on the wire. The company homepage is product-home context, not a second originating newsroom. The JAMA Cardiology paper is the study the wire cites. This desk did not get past the journal’s bot check, so the performance numbers stay the wire’s. The $24 million Series B2, Alive HealthTech Growth Fund as lead, Deep Insight, Star51 Capital, Connecticut Innovations, eHealth Ventures, the existing Mayo Clinic Ventures, NYU, and Iron Nation lines, the U.S. commercial expansion, the ICU and circulatory-support workflows, the Echosystem description, the single 510(k) sentence, the more-than-10 commercial sites, the Vortman, Klein, Beyar, and Geoffrion quotes, Geoffrion’s chair and the three board welcomes, and the Mayo financial-interest disclosure are the release’s. The Cambridge address, the EchoSystem spelling, the pivotal-study majority line, the twelve-studies line, the under-five-minutes line, the unnamed head-to-head, and the Circulation journal line are the homepage’s. NOT claimed: a valuation, a per-investor split, a second named FDA clearance, hospital names, that this desk re-ran the 93 percent or 96 percent figures, that the Circulation paper and the JAMA Cardiology paper are the same study, that “will welcome” means the directors have already sat, a stock tip, or investment advice. Distinct from the already-filed enveda-311m, basecamp-research-140m, and powerful-medical-queen-of-hearts-fda-de-novo.